Medikit Co.,Ltd. carries a market capitalization of 40.48B, placing it among publicly traded companies globally. Its enterprise value stands at 19.95B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 40.48B |
| Enterprise Value | 19.95B |
Medikit Co.,Ltd. currently has 14.81M shares outstanding.
| Shares Outstanding | 14.81M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Medikit Co.,Ltd. trades at a trailing price-to-earnings ratio of 24.47. The price-to-sales ratio is 3.89, and the price-to-book ratio stands at 1.03.
| PE Ratio | 24.47 |
| PS Ratio | 3.89 |
| PB Ratio | 1.03 |
| P/TBV Ratio | 1.04 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
On an enterprise value basis, Medikit Co.,Ltd. trades at an EV/EBITDA multiple of 8.31 and an EV/FCF ratio of 7,088.05. The EV/Sales ratio of 1.81 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 8.31 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.81 |
| EV / EBITDA | 8.31 |
| EV / EBIT | 8.31 |
| EV / FCF | 7,088.05 |
Medikit Co.,Ltd. maintains a current ratio of 5.45, meaning it holds 5.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 5.45 |
| Quick Ratio | 3.66 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | 627.55 |
Medikit Co.,Ltd. posts a return on equity of 4.30 and a return on invested capital of 3.75.
| Return on Equity (ROE) | 4.30 |
| Return on Assets (ROA) | 3.29 |
| Return on Invested Capital (ROIC) | 3.75 |
| Return on Capital Employed (ROCE) | 4.31 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.75 |
Over the trailing twelve months, Medikit Co.,Ltd. has paid 628.22M in income taxes, reflecting an effective tax rate of 26.43.
| Income Tax | 628.22M |
| Effective Tax Rate | 26.43 |
Medikit Co.,Ltd.'s stock has gained approximately 9.38967% over the past 52 weeks. The 50-day moving average sits at 2,877.66, while the 200-day moving average is 2,887.24.
| Beta (5Y) | N/A |
| 52-Week Price Change | 9.38967% |
| 50-Day Moving Average | 2,877.66 |
| 200-Day Moving Average | 2,887.24 |
| Average Volume (20 Days) | N/A |
Over the trailing twelve months, Medikit Co.,Ltd. generated 11.00B in revenue and converted that into 1.75B in net income, yielding earnings per share of 118.19. EBITDA reached 2.40B, while operating income came in at 2.40B.
| Revenue | 11.00B |
| Gross Profit | 4.34B |
| Operating Income | 2.40B |
| Pretax Income | 2.38B |
| Net Income | 1.75B |
| EBITDA | 2.40B |
| EBIT | 2.40B |
| Earnings Per Share (EPS) | 118.19 |
Total book value stands at 41.47B, with working capital of 27.77B providing operational flexibility.
| Cash & Cash Equivalents | 22.84B |
| Total Debt | N/A |
| Net Debt | -22.84B |
| Equity (Book Value) | 41.47B |
| Book Value Per Share | 2,802.43 |
| Working Capital | 27.77B |
Medikit Co.,Ltd. operates with a gross margin of 39.45, reflecting its pricing power and cost economics. The operating margin of 21.82 and net profit margin of 15.89 provide insight into operational efficiency.
| Gross Margin | 39.45 |
| Operating Margin | 21.82 |
| Pretax Margin | 21.60 |
| Profit Margin | 15.89 |
| EBITDA Margin | 21.82 |
Medikit Co.,Ltd.'s most recent stock split took place on March 30, 2020 with a 1:2 split ratio.
| Last Split Date | 3/30/2020 |
| Split Ratio | 1:2 |
Medikit Co.,Ltd. posts an Altman Z-Score of 5.69, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 5.69 |